Show simple item record

dc.contributor.authorShaz, Beth H.
dc.contributor.authorLinenberger, Michael L.
dc.contributor.authorBandarenko, Nicholas
dc.contributor.authorWinters, Jeffrey L.
dc.contributor.authorKim, Haewon C.
dc.contributor.authorMarques, Marisa B.
dc.contributor.authorSarode, Ravindra
dc.contributor.authorSchwartz, Joseph
dc.contributor.authorWeinstein, Robert
dc.contributor.authorWirk, Ashka
dc.contributor.authorSzczepiorkowski, Zbigniew M.
dc.date2022-08-11T08:11:00.000
dc.date.accessioned2022-08-23T17:28:33Z
dc.date.available2022-08-23T17:28:33Z
dc.date.issued2007-03-23
dc.date.submitted2010-03-15
dc.identifier.citationJ Clin Apher. 2007 Jun;22(3):176-80. <a href="http://dx.doi.org/10.1002/jca.20131">Link to article on publisher's site</a>
dc.identifier.issn0733-2459 (Linking)
dc.identifier.doi10.1002/jca.20131
dc.identifier.pmid17377982
dc.identifier.urihttp://hdl.handle.net/20.500.14038/50106
dc.description.abstractThe American Society for Apheresis (ASFA) Committee on Clinical Applications systematically and critically reviews published information on the use of therapeutic apheresis in clinical practice. On the basis of this review, selected diseases are assigned one of five categories (category I, II, III, IV, and P). The diseases, which were classified as category IV indications, and the rationale for such assignment are reviewed in this article. The diseases assigned to category I, II, III, and newly created category P are discussed in a separate article in this issue.
dc.language.isoen_US
dc.relation<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=pubmed&cmd=Retrieve&list_uids=17377982&dopt=Abstract">Link to Article in PubMed</a>
dc.relation.urlhttp://dx.doi.org/10.1002/jca.20131
dc.subject*Blood Component Removal
dc.subjectDisease
dc.subjectHumans
dc.subjectPractice Guidelines as Topic
dc.subjectSocieties, Medical
dc.subjectUnited States
dc.subjectHemic and Immune Systems
dc.subjectOther Medical Specialties
dc.titleCategory IV indications for therapeutic apheresis: ASFA fourth special issue
dc.typeJournal Article
dc.source.journaltitleJournal of clinical apheresis
dc.source.volume22
dc.source.issue3
dc.identifier.legacycoverpagehttps://escholarship.umassmed.edu/transfusion_pp/5
dc.identifier.contextkey1223015
html.description.abstract<p>The American Society for Apheresis (ASFA) Committee on Clinical Applications systematically and critically reviews published information on the use of therapeutic apheresis in clinical practice. On the basis of this review, selected diseases are assigned one of five categories (category I, II, III, IV, and P). The diseases, which were classified as category IV indications, and the rationale for such assignment are reviewed in this article. The diseases assigned to category I, II, III, and newly created category P are discussed in a separate article in this issue.</p>
dc.identifier.submissionpathtransfusion_pp/5
dc.contributor.departmentDepartment of Medicine, Division of Transfusion Medicine
dc.source.pages176-80


This item appears in the following Collection(s)

Show simple item record